Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation
ZBIO•Pipeline update and cash runway
The pipeline update highlighted orelabrutinib Phase 3 programs in PPMS and naSPMS, with trials initiated in 3Q 2025 and 1Q 2026.
The company projected cash runway into 2029, positioning it to commercialize and advance multiple immunology and inflammation programs.
Corporate presentation outlines pipeline and regulatory path
Zenas Biopharma outlined a regulatory path for obexelimab in IgG4-RD, with an FDA decision expected by May 2027.
The company said its Phase 3 INDIGO trial met its primary endpoint, cutting flare risk 56% versus placebo; 73% of patients were flare-free at week 52.
Key secondary endpoints favored obexelimab, including a 37.1% complete remission rate at week 52 versus 19.6% on placebo.
